Sanofi-GSK COVID vax shows strong immune responses in Phase 2 trial
A COVID-19 vaccine developed by pharmaceutical giants Sanofi and Glaxo Smith Kline (GSK) has shown strong rates of neutralising antibody responses against the infectious Coronavirus disease in the Phase-II trial.
May 18, 2021, 14:10 PM IST